Eosinophilic Esophagitis Treatment for Patients

THE FIRST AND ONLY
TREATMENT FOR
EoE PATIENTS
AS YOUNG AS 1 YEAR OLD

DUPIXENT is indicated for the treatment of adult and pediatric patients aged 1 year
and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).¹

TRANSFORM THE WAY
YOU MANAGE EoE

Discover clinical, histologic,
and
endoscopic results^1-3

NOW APPROVED in children as
young as 1 year with EoE (≥15 kg)¹

EXPLORE UP TO 52 WEEKS OF DATA FOR BOTH GROUPS^1-3

Adults/Adolescents
(12+ years)

VIEW THE Efficacy RESULTS EXPLORE THE Safety DATA

Children (1-11 years)

VIEW THE Efficacy RESULTS EXPLORE THE Safety DATA

DUPIXENT MyWay® is a patient support
program
that can help
enable access to
DUPIXENT
and offers financial assistance
for
eligible
patients, one-on-one nursing
support, and more.

LEARN HOW WE CAN HELP

*DUPIXENT MyWay* ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form

Contact a Field
Representative

Connect with a DUPIXENT Field Representative to get answers to your product-related questions.

CONTACT A REP

THE FIRST AND ONLY TREATMENT FOR EoE PATIENTS AS YOUNG AS 1 YEAR OLD

EXPLORE UP TO 52 WEEKS OF DATA FOR BOTH GROUPS1-3

Adults/Adolescents (12+ years)

Children (1-11 years)

DUPIXENT MyWay ENROLLMENT FORMS

Contact a Field Representative

Are you sure you want to leave?

Are you sure you want to leave?

THE FIRST AND ONLY
TREATMENT FOR
EoE PATIENTS
AS YOUNG AS 1 YEAR OLD

EXPLORE UP TO 52 WEEKS OF DATA FOR BOTH GROUPS^1-3

Adults/Adolescents
(12+ years)

DUPIXENT MyWay
ENROLLMENT FORMS

Contact a Field
Representative